Placebo-controlled trial of amantadine for severe traumatic brain injury

Joseph T. Giacino, John Whyte, Emilia Bagiella, Kathleen Kalmar, Nancy Childs, Allen Khademi, Bernd Eifert, David Long, Douglas I. Katz, Sooja Cho, Stuart A. Yablon, Marianne Luther, Flora Hammond, Annette Nordenbo, Paul Novak, Walt Mercer, Petra Maurer-Karattup, Mark Sherer

Research output: Contribution to journalArticle

306 Citations (Scopus)

Abstract

BACKGROUND: Amantadine hydrochloride is one of the most commonly prescribed medications for patients with prolonged disorders of consciousness after traumatic brain injury. Preliminary studies have suggested that amantadine may promote functional recovery. METHODS: We enrolled 184 patients who were in a vegetative or minimally conscious state 4 to 16 weeks after traumatic brain injury and who were receiving inpatient rehabilitation. Patients were randomly assigned to receive amantadine or placebo for 4 weeks and were followed for 2 weeks after the treatment was discontinued. The rate of functional recovery on the Disability Rating Scale (DRS; range, 0 to 29, with higher scores indicating greater disability) was compared over the 4 weeks of treatment (primary outcome) and during the 2-week washout period with the use of mixed-effects regression models. RESULTS: During the 4-week treatment period, recovery was significantly faster in the amantadine group than in the placebo group, as measured by the DRS score (difference in slope, 0.24 points per week; P = 0.007), indicating a benefit with respect to the primary outcome measure. In a prespecified subgroup analysis, the treatment effect was similar for patients in a vegetative state and those in a minimally conscious state. The rate of improvement in the amantadine group slowed during the 2 weeks after treatment (weeks 5 and 6) and was significantly slower than the rate in the placebo group (difference in slope, 0.30 points per week; P = 0.02). The overall improvement in DRS scores between baseline and week 6 (2 weeks after treatment was discontinued) was similar in the two groups. There were no significant differences in the incidence of serious adverse events. CONCLUSIONS: Amantadine accelerated the pace of functional recovery during active treatment in patients with post-traumatic disorders of consciousness. (Funded by the National Institute on Disability and Rehabilitation Research; ClinicalTrials.gov number, NCT00970944.)

Original languageEnglish
Pages (from-to)819-826
Number of pages8
JournalNew England Journal of Medicine
Volume366
Issue number9
DOIs
StatePublished - Mar 1 2012

Fingerprint

Amantadine
Placebos
Persistent Vegetative State
Consciousness Disorders
Therapeutics
Traumatic Brain Injury
Inpatients
Rehabilitation
Outcome Assessment (Health Care)
Incidence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Giacino, J. T., Whyte, J., Bagiella, E., Kalmar, K., Childs, N., Khademi, A., ... Sherer, M. (2012). Placebo-controlled trial of amantadine for severe traumatic brain injury. New England Journal of Medicine, 366(9), 819-826. https://doi.org/10.1056/NEJMoa1102609

Placebo-controlled trial of amantadine for severe traumatic brain injury. / Giacino, Joseph T.; Whyte, John; Bagiella, Emilia; Kalmar, Kathleen; Childs, Nancy; Khademi, Allen; Eifert, Bernd; Long, David; Katz, Douglas I.; Cho, Sooja; Yablon, Stuart A.; Luther, Marianne; Hammond, Flora; Nordenbo, Annette; Novak, Paul; Mercer, Walt; Maurer-Karattup, Petra; Sherer, Mark.

In: New England Journal of Medicine, Vol. 366, No. 9, 01.03.2012, p. 819-826.

Research output: Contribution to journalArticle

Giacino, JT, Whyte, J, Bagiella, E, Kalmar, K, Childs, N, Khademi, A, Eifert, B, Long, D, Katz, DI, Cho, S, Yablon, SA, Luther, M, Hammond, F, Nordenbo, A, Novak, P, Mercer, W, Maurer-Karattup, P & Sherer, M 2012, 'Placebo-controlled trial of amantadine for severe traumatic brain injury', New England Journal of Medicine, vol. 366, no. 9, pp. 819-826. https://doi.org/10.1056/NEJMoa1102609
Giacino JT, Whyte J, Bagiella E, Kalmar K, Childs N, Khademi A et al. Placebo-controlled trial of amantadine for severe traumatic brain injury. New England Journal of Medicine. 2012 Mar 1;366(9):819-826. https://doi.org/10.1056/NEJMoa1102609
Giacino, Joseph T. ; Whyte, John ; Bagiella, Emilia ; Kalmar, Kathleen ; Childs, Nancy ; Khademi, Allen ; Eifert, Bernd ; Long, David ; Katz, Douglas I. ; Cho, Sooja ; Yablon, Stuart A. ; Luther, Marianne ; Hammond, Flora ; Nordenbo, Annette ; Novak, Paul ; Mercer, Walt ; Maurer-Karattup, Petra ; Sherer, Mark. / Placebo-controlled trial of amantadine for severe traumatic brain injury. In: New England Journal of Medicine. 2012 ; Vol. 366, No. 9. pp. 819-826.
@article{e830031d8a4a46fbb6a6c2f1e100d116,
title = "Placebo-controlled trial of amantadine for severe traumatic brain injury",
abstract = "BACKGROUND: Amantadine hydrochloride is one of the most commonly prescribed medications for patients with prolonged disorders of consciousness after traumatic brain injury. Preliminary studies have suggested that amantadine may promote functional recovery. METHODS: We enrolled 184 patients who were in a vegetative or minimally conscious state 4 to 16 weeks after traumatic brain injury and who were receiving inpatient rehabilitation. Patients were randomly assigned to receive amantadine or placebo for 4 weeks and were followed for 2 weeks after the treatment was discontinued. The rate of functional recovery on the Disability Rating Scale (DRS; range, 0 to 29, with higher scores indicating greater disability) was compared over the 4 weeks of treatment (primary outcome) and during the 2-week washout period with the use of mixed-effects regression models. RESULTS: During the 4-week treatment period, recovery was significantly faster in the amantadine group than in the placebo group, as measured by the DRS score (difference in slope, 0.24 points per week; P = 0.007), indicating a benefit with respect to the primary outcome measure. In a prespecified subgroup analysis, the treatment effect was similar for patients in a vegetative state and those in a minimally conscious state. The rate of improvement in the amantadine group slowed during the 2 weeks after treatment (weeks 5 and 6) and was significantly slower than the rate in the placebo group (difference in slope, 0.30 points per week; P = 0.02). The overall improvement in DRS scores between baseline and week 6 (2 weeks after treatment was discontinued) was similar in the two groups. There were no significant differences in the incidence of serious adverse events. CONCLUSIONS: Amantadine accelerated the pace of functional recovery during active treatment in patients with post-traumatic disorders of consciousness. (Funded by the National Institute on Disability and Rehabilitation Research; ClinicalTrials.gov number, NCT00970944.)",
author = "Giacino, {Joseph T.} and John Whyte and Emilia Bagiella and Kathleen Kalmar and Nancy Childs and Allen Khademi and Bernd Eifert and David Long and Katz, {Douglas I.} and Sooja Cho and Yablon, {Stuart A.} and Marianne Luther and Flora Hammond and Annette Nordenbo and Paul Novak and Walt Mercer and Petra Maurer-Karattup and Mark Sherer",
year = "2012",
month = "3",
day = "1",
doi = "10.1056/NEJMoa1102609",
language = "English",
volume = "366",
pages = "819--826",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "9",

}

TY - JOUR

T1 - Placebo-controlled trial of amantadine for severe traumatic brain injury

AU - Giacino, Joseph T.

AU - Whyte, John

AU - Bagiella, Emilia

AU - Kalmar, Kathleen

AU - Childs, Nancy

AU - Khademi, Allen

AU - Eifert, Bernd

AU - Long, David

AU - Katz, Douglas I.

AU - Cho, Sooja

AU - Yablon, Stuart A.

AU - Luther, Marianne

AU - Hammond, Flora

AU - Nordenbo, Annette

AU - Novak, Paul

AU - Mercer, Walt

AU - Maurer-Karattup, Petra

AU - Sherer, Mark

PY - 2012/3/1

Y1 - 2012/3/1

N2 - BACKGROUND: Amantadine hydrochloride is one of the most commonly prescribed medications for patients with prolonged disorders of consciousness after traumatic brain injury. Preliminary studies have suggested that amantadine may promote functional recovery. METHODS: We enrolled 184 patients who were in a vegetative or minimally conscious state 4 to 16 weeks after traumatic brain injury and who were receiving inpatient rehabilitation. Patients were randomly assigned to receive amantadine or placebo for 4 weeks and were followed for 2 weeks after the treatment was discontinued. The rate of functional recovery on the Disability Rating Scale (DRS; range, 0 to 29, with higher scores indicating greater disability) was compared over the 4 weeks of treatment (primary outcome) and during the 2-week washout period with the use of mixed-effects regression models. RESULTS: During the 4-week treatment period, recovery was significantly faster in the amantadine group than in the placebo group, as measured by the DRS score (difference in slope, 0.24 points per week; P = 0.007), indicating a benefit with respect to the primary outcome measure. In a prespecified subgroup analysis, the treatment effect was similar for patients in a vegetative state and those in a minimally conscious state. The rate of improvement in the amantadine group slowed during the 2 weeks after treatment (weeks 5 and 6) and was significantly slower than the rate in the placebo group (difference in slope, 0.30 points per week; P = 0.02). The overall improvement in DRS scores between baseline and week 6 (2 weeks after treatment was discontinued) was similar in the two groups. There were no significant differences in the incidence of serious adverse events. CONCLUSIONS: Amantadine accelerated the pace of functional recovery during active treatment in patients with post-traumatic disorders of consciousness. (Funded by the National Institute on Disability and Rehabilitation Research; ClinicalTrials.gov number, NCT00970944.)

AB - BACKGROUND: Amantadine hydrochloride is one of the most commonly prescribed medications for patients with prolonged disorders of consciousness after traumatic brain injury. Preliminary studies have suggested that amantadine may promote functional recovery. METHODS: We enrolled 184 patients who were in a vegetative or minimally conscious state 4 to 16 weeks after traumatic brain injury and who were receiving inpatient rehabilitation. Patients were randomly assigned to receive amantadine or placebo for 4 weeks and were followed for 2 weeks after the treatment was discontinued. The rate of functional recovery on the Disability Rating Scale (DRS; range, 0 to 29, with higher scores indicating greater disability) was compared over the 4 weeks of treatment (primary outcome) and during the 2-week washout period with the use of mixed-effects regression models. RESULTS: During the 4-week treatment period, recovery was significantly faster in the amantadine group than in the placebo group, as measured by the DRS score (difference in slope, 0.24 points per week; P = 0.007), indicating a benefit with respect to the primary outcome measure. In a prespecified subgroup analysis, the treatment effect was similar for patients in a vegetative state and those in a minimally conscious state. The rate of improvement in the amantadine group slowed during the 2 weeks after treatment (weeks 5 and 6) and was significantly slower than the rate in the placebo group (difference in slope, 0.30 points per week; P = 0.02). The overall improvement in DRS scores between baseline and week 6 (2 weeks after treatment was discontinued) was similar in the two groups. There were no significant differences in the incidence of serious adverse events. CONCLUSIONS: Amantadine accelerated the pace of functional recovery during active treatment in patients with post-traumatic disorders of consciousness. (Funded by the National Institute on Disability and Rehabilitation Research; ClinicalTrials.gov number, NCT00970944.)

UR - http://www.scopus.com/inward/record.url?scp=84857826580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857826580&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa1102609

DO - 10.1056/NEJMoa1102609

M3 - Article

VL - 366

SP - 819

EP - 826

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 9

ER -